Daily Roundup
Thursday, 19th November 2026 · updated 15:00
New Hope Corporation Rewards Shareholders with Interim Dividend
New Hope Corporation is returning cash to shareholders with a fully franked first interim dividend of 15 cents per share. The payment will hit accounts on 10 February 2027, with the record date falling on 29 January 2027. The company's decision reflects strong free cash flow generation and buoyant coal market conditions, and management expects to consider a second interim dividend later in the financial year. The dividend is funded directly from operational cash flow, signalling confidence in the company's ability to sustain shareholder returns while maintaining operational flexibility.
Chrysos Corporation Firing on All Cylinders
Things are looking bright at Chrysos Corporation, which just released a pre-AGM trading update showing impressive momentum. The company's PhotonAssay technology is gaining serious traction—revenue jumped 27% to $36.7 million in the first four months of FY27, while sample volumes hit a record 4.91 million, up 43% year-over-year. October alone was a standout month with 1.36 million samples processed.
The lease agreement pipeline is equally encouraging. Chrysos signed 15 new PhotonAssay lease agreements, with 11 coming since August, bringing the total contracted fleet to 973 units. The company has deployed six new units with another six currently rolling out, expanding its global footprint across five continents. With cash holdings of $19.5 million and $120 million in undrawn debt capacity, Chrysos is well-positioned to capitalize on momentum. Management has reaffirmed FY27 guidance of $108 million to $118 million in revenue and $35 million to $42 million in EBITDA, while eyeing a fleet expansion to 90 deployed units by the end of FY29.
Close the Loop Strengthens Balance Sheet
Close the Loop delivered a solid first quarter with $32.4 million in revenue and $4.3 million in EBITDA. More importantly, the company has materially strengthened its financial position by settling $24.4 million of convertible notes, slashing net debt to $16.3 million. Citi Bank has approved a refinancing of the group's debt facility, expected to complete by mid-December, which should reduce interest costs and ease quarterly principal repayments. The company reaffirmed its FY27 EBITDA guidance of $14.0 million to $16.0 million and signalled it's tracking toward the upper end of that range. Leadership also shifted, with Trifon Dimos taking the chair and Grant Carman moving to a non-executive role.
Emeco Expects Utilisation to Pick Up
Equipment rental specialist Emeco Holdings provided a measured outlook for FY27. While utilisation moderated during calendar 2026, the company has seen improvement in the second quarter and expects that trend to continue through the second half. Emeco is forecasting operating EBITDA between $275 million and $285 million, with heavier weighting to H2, alongside capex of $155 million to $160 million. The company believes improving utilisation rates will set it up to deliver earnings growth aligned with its 20% return on capital target in FY28.
BCAL Signals Support for GSS-MAP Merger
BCAL Diagnostics, the largest shareholder of Genetic Signatures, has indicated it's prepared to support the proposed merger between GSS and Microba Life Sciences on appropriate terms. BCAL would even consider providing up to $2 million in funding to MAP for working capital, subject to its own capital raising. However, BCAL's backing comes with conditions, including a restructure of the GSS Board and the resignation of the GSS Chair.